Treatment with AP01, Avalyn Pharma‘s experimental inhaled formulation of pirfenidone, appears to be slightly more effective for idiopathic pulmonary fibrosis (IPF) than the oral version, which is sold as Esbriet, and results in fewer side effects. AP01’s efficacy and safety profiles with progressive forms of pulmonary…
Read more
Have you ever read a book that totally resonated with you? One that reflects who you are and enables you to see yourself in the words? I love to read a variety of genres but tend to lean toward self-improvement, technical publications, and real-life stories. A longtime friend of mine, following…
The experimental oral therapy BMS-986278, taken at 60 mg twice daily for 26 weeks, resulted in a 69% reduction in the rate of lung function decline in adults with progressive pulmonary fibrosis taking part in a Phase 2 trial. These findings are consistent with previously reported data from…
Columnist Sam Kirton looks ahead to the Pulmonary Fibrosis Foundation Summit in November and encourages the PF community to attend.
Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.
Becoming educated and informed about PF is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your PF journey.
There is no cure for PF yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
